[go: up one dir, main page]

WO2024062072A3 - Anticorps monoclonaux anti-ccr8 et leur usage thérapeutique - Google Patents

Anticorps monoclonaux anti-ccr8 et leur usage thérapeutique Download PDF

Info

Publication number
WO2024062072A3
WO2024062072A3 PCT/EP2023/076151 EP2023076151W WO2024062072A3 WO 2024062072 A3 WO2024062072 A3 WO 2024062072A3 EP 2023076151 W EP2023076151 W EP 2023076151W WO 2024062072 A3 WO2024062072 A3 WO 2024062072A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccr8
antigen
binding fragment
monoclonal antibodies
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/076151
Other languages
English (en)
Other versions
WO2024062072A2 (fr
Inventor
Christel Franchet
Alice GENTIL DIT MAURIN
Dounia CHRAA
Iseulys RICHERT
Orphée BLANCHARD
Xavier Leroy
Claudine Vermot-Desroches
Julien ISOARD
Yannick Nizet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domain Therapeutics SA
Original Assignee
Domain Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL319678A priority Critical patent/IL319678A/en
Priority to JP2025517339A priority patent/JP2025531392A/ja
Priority to CN202380080115.3A priority patent/CN120476142A/zh
Priority to CA3268044A priority patent/CA3268044A1/fr
Priority to KR1020257012888A priority patent/KR20250111754A/ko
Priority to EP23776067.3A priority patent/EP4590702A2/fr
Priority to AU2023345465A priority patent/AU2023345465A1/en
Application filed by Domain Therapeutics SA filed Critical Domain Therapeutics SA
Publication of WO2024062072A2 publication Critical patent/WO2024062072A2/fr
Publication of WO2024062072A3 publication Critical patent/WO2024062072A3/fr
Priority to EP24772391.9A priority patent/EP4590715A1/fr
Priority to PCT/EP2024/076512 priority patent/WO2025061994A1/fr
Priority to MX2025003314A priority patent/MX2025003314A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un anticorps monoclonal ou un fragment de liaison à l'antigène de celui-ci, qui se lie spécifiquement au CCR8 humain et est un antagoniste de la voie de signalisation CCL1-CCR8, en particulier l'anticorps ou le fragment de liaison à l'antigène se liant spécifiquement au CCR8 humain indépendamment de la présence ou de l'absence de modifications post-traductionnelles, telles que des résidus tyrosine sulfatés aux positions 15, 16 et/ou 17 du CCR8 humain. L'invention concerne également l'anticorps ou le fragment de liaison à l'antigène destiné à être utilisé en thérapie, en particulier dans le traitement du cancer.
PCT/EP2023/076151 2022-09-21 2023-09-21 Anticorps monoclonaux anti-ccr8 et leur usage thérapeutique Ceased WO2024062072A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2023345465A AU2023345465A1 (en) 2022-09-21 2023-09-21 Anti-ccr8 monoclonal antibodies and their therapeutic use
CN202380080115.3A CN120476142A (zh) 2022-09-21 2023-09-21 抗ccr8单克隆抗体及其治疗用途
CA3268044A CA3268044A1 (fr) 2022-09-21 2023-09-21 Anticorps monoclonaux anti-ccr8 et leur usage thérapeutique
KR1020257012888A KR20250111754A (ko) 2022-09-21 2023-09-21 항-ccr8 모노클로날 항체 및 이의 치료적 용도
EP23776067.3A EP4590702A2 (fr) 2022-09-21 2023-09-21 Anticorps monoclonaux anti-ccr8 et leur usage thérapeutique
IL319678A IL319678A (en) 2022-09-21 2023-09-21 Anti-CCR8 monoclonal antibodies and their medical use
JP2025517339A JP2025531392A (ja) 2022-09-21 2023-09-21 抗ｃｃｒ８モノクローナル抗体およびそれらの治療的使用
PCT/EP2024/076512 WO2025061994A1 (fr) 2023-09-21 2024-09-20 Anticorps monoclonaux anti-ccr8 et leur utilisation thérapeutique
EP24772391.9A EP4590715A1 (fr) 2023-09-21 2024-09-20 Anticorps monoclonaux anti-ccr8 et leur utilisation thérapeutique
MX2025003314A MX2025003314A (es) 2022-09-21 2025-03-20 Anticuerpos monoclonales anti-ccr8 y su uso terapeutico

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22306388 2022-09-21
EP22306388.4 2022-09-21

Publications (2)

Publication Number Publication Date
WO2024062072A2 WO2024062072A2 (fr) 2024-03-28
WO2024062072A3 true WO2024062072A3 (fr) 2024-05-10

Family

ID=83689153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/076151 Ceased WO2024062072A2 (fr) 2022-09-21 2023-09-21 Anticorps monoclonaux anti-ccr8 et leur usage thérapeutique

Country Status (1)

Country Link
WO (1) WO2024062072A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025226603A1 (fr) * 2024-04-22 2025-10-30 Surface Oncology, LLC Méthodes de traitement d'un cancer à l'aide d'anticorps anti-ccr8

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142002A1 (fr) * 2020-01-06 2021-07-15 Vaccinex, Inc. Anticorps anti-ccr8 et leurs utilisations
WO2021194942A1 (fr) * 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Anticorps anti-ccr8 pour le traitement du cancer
EP3903817A1 (fr) * 2018-12-27 2021-11-03 Shionogi & Co., Ltd. Nouvel anticorps anti-ccr8
WO2021260210A2 (fr) * 2020-06-26 2021-12-30 Bayer Aktiengesellschaft Thérapie par anticorps anti-ccr8 : biomarqueurs et polythérapies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR500E (fr) 1901-11-05 1903-01-26 Castencau Adrien Un nouveau système de mécanisme d'horlogerie donnant la division du jour en vingt-quatre heures
FR20216E (fr) 1913-12-31 1917-03-14 United Shoe Machinery Co Fr Perfectionnements aux machines de cordonnerie
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2007044756A2 (fr) 2005-10-11 2007-04-19 Icos Corporation Anticorps monoclonaux reconnaissant le ccr8 humain
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
WO2018112032A1 (fr) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Procédés et compositions pour le ciblage de lymphocytes t régulateurs infiltrant les tumeurs
RU2730984C1 (ru) 2017-03-29 2020-08-26 Сионоги Энд Ко., Лтд. Фармацевтическая композиция для лечения злокачественного новообразования
WO2022003156A1 (fr) 2020-07-02 2022-01-06 Oncurious Nv Liants non bloquants ccr8
WO2022042690A1 (fr) 2020-08-28 2022-03-03 和铂医药(上海)有限责任公司 Anticorps anti-ccr8 et application correspondante
CN116589583A (zh) 2020-10-16 2023-08-15 礼新医药科技(上海)有限公司 抗ccr8单克隆抗体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3903817A1 (fr) * 2018-12-27 2021-11-03 Shionogi & Co., Ltd. Nouvel anticorps anti-ccr8
WO2021142002A1 (fr) * 2020-01-06 2021-07-15 Vaccinex, Inc. Anticorps anti-ccr8 et leurs utilisations
WO2021194942A1 (fr) * 2020-03-23 2021-09-30 Bristol-Myers Squibb Company Anticorps anti-ccr8 pour le traitement du cancer
WO2021260210A2 (fr) * 2020-06-26 2021-12-30 Bayer Aktiengesellschaft Thérapie par anticorps anti-ccr8 : biomarqueurs et polythérapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHENG DIWEI ET AL: "The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies", vol. 13, 26 May 2022 (2022-05-26), pages 1 - 11, XP093005330, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182403/pdf/fimmu-13-808347.pdf> DOI: 10.3389/fimmu.2022.808347 *

Also Published As

Publication number Publication date
WO2024062072A2 (fr) 2024-03-28

Similar Documents

Publication Publication Date Title
US9409976B2 (en) CDIM binding proteins and uses thereof
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
WO2024062072A3 (fr) Anticorps monoclonaux anti-ccr8 et leur usage thérapeutique
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
IL276695A (en) Antibodies, pharmaceuticals and their uses
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
RU2013136172A (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
UA89350C2 (uk) Гуманізоване антитіло, що зв&#39;язує людський cd20
ZA202202363B (en) Antibodies against ilt2 and use thereof
RU2010141584A (ru) Антитело против csf-1r
EP4435009A3 (fr) Anticorps anti-claudine6 et méthodes de traitement du cancer
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
GEP20074222B (en) Antibodies to cd40
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
MA30654B1 (fr) Therapie tumorale avec anticorps anti-vegf
ECSP099683A (es) Proteinas de union incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos que se unen especificamente a cd154 y sus usos.
CN109963592A (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
EA202091747A1 (ru) Составы антитела b7-h4
WO2017060322A3 (fr) Conjugué anticorps-médicament (adc) inhibiteur de ptefb
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2023010567A (es) Variantes de anticuerpos no activadoras.
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23776067

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 319678

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/003314

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2025517339

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025517339

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025005451

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: AU2023345465

Country of ref document: AU

Ref document number: 820613

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 202517036956

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2023776067

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023345465

Country of ref document: AU

Date of ref document: 20230921

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2023776067

Country of ref document: EP

Effective date: 20250422

WWE Wipo information: entry into national phase

Ref document number: 202380080115.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: MX/A/2025/003314

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 202517036956

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1020257012888

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2023776067

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 202380080115.3

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112025005451

Country of ref document: BR

Free format text: APRESENTAR NOVAS FOLHAS REFERENTES AO RELATORIO DESCRITIVO, ADAPTADAS AO ART. 20 DA PORTARIA/INPI/NO 14/2024, UMA VEZ QUE TODAS AS TABELAS INSERIDAS NO TEXTO DEVEM SER IDENTIFICADAS DE FORMA SEQUENCIAL. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO, POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207.

ENP Entry into the national phase

Ref document number: 112025005451

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250320